Daiichi Sankyo Korea & Daewoong Pharmaceutical Signs Agreement to co market LIXIANA® in South Korea
Daiichi Sankyo Company, Limited announced that its wholly owned subsidiary, Daiichi Sankyo Korea Co., Ltd. (hereafter “DSKR;” headquarters: Jongno-gu, Seoul, South Korea), and Daewoong Pharmaceutical Co., Ltd. (hereafter “Daewoong Pharmaceutical;” headquarter: Gangnam-gu, Seoul, South Korea) have signed an agreement for the co-promotion of the oral, once-daily anti-coagulant, LIXIANA® (generic name: edoxaban).
[adsense:336x280:8701650588]
Daewoong Pharmaceutical is also the co-promotion partner in South Korea for the Daiichi Sankyo antihypertensives Olmetec®, Olmetec Plus®, Sevikar®, Sevikar HCT®, and through this new agreement, Daiichi Sankyo Korea aims to maximize LIXIANA’s product value and further contribute to disease treatment and prevention in South Korea.
[adsense:468x15:2204050025]
LIXIANA was approved in South Korea in August 2015 and will be launched within this fiscal year.